Effects of Wu-chu-yu-tang and its component herbs on drug-metabolizing enzymes

被引:25
作者
Ueng, YF
Don, MJ
Peng, HC
Wang, SY
Wang, JJ
Chen, CF
机构
[1] Natl Res Inst Chinese Med, Taipei 112, Taiwan
[2] Natl Yang Ming Univ, Inst Bio Pharmaceut Sci, Taipei 112, Taiwan
关键词
Wu-chu-yu-tang; Evodiae Fructus; rutaecarpine; drug-metabolizing enzyme; liver;
D O I
10.1254/jjp.89.267
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The compound herbal medicine Wu-chu-yu-tang is used for the treatment of migraine and vomiting accompanying a cold. To assess the interactions of herb and drug metabolism, effects of Wu-chu-yu-tang on hepatic and renal cytochrome P450 (CYP), UDP-glucuronosyl transferase (UGT) and glutathione S-transferase (GST) were studied in C57BL/6J mice. Treatment of mice with 5 g/kg per day Wu-chu-yu-tang for 3 days caused 2.5-fold and 2.9-fold increases of liver microsomal 7-ethoxyresorufin O-deethylation (EROD) and 7-methoxyresorufin O-demethylation activities, respectively. However, CYP activities toward 7-ethoxycoumarin, benzphetamine, N-nitrosodimethylamine, erythromycin and nifedipine, and conjugation activities of UGT and GST were not affected. In kidney, Wu-chu-yu-tang-treatment had no effects on Cyp, UGT and GST activities. Among the four component herbs of Wu-chu-yu-tang, only Evodiae Fructus (Wu-chu-yu) extract increased EROD activity and CYP1a2 protein level. In E. Fructus, rutaecarpine, evodiamine and dehydroevodiamine are the main active alkaloids. At the doses corresponding to their contents in Wu-chu-yu-tang, rutaecarpine-treatment increased hepatic EROD activity, whereas evodiamine and dehydroevodiamine had no effects. These results demonstrated that ingestion of Wu-chu-yu-tang elevated mouse hepatic Cyp1a2 activity and protein level. E. Fructus and rutaecarpine contributed at least in part to the CYP1a2 induction by Wu-chu-yu-tang. Patients should be cautioned about the drug interaction of Wu-chu-yu-tang and CYP1A2 substrates.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 26 条
[1]  
ALVARES AP, 1970, MOL PHARMACOL, V6, P206
[2]   STUDIES OF RUTAECARPINE AND RELATED QUINAZOLINOCARBOLINE ALKALOIDS [J].
BERGMAN, J ;
BERGMAN, S .
JOURNAL OF ORGANIC CHEMISTRY, 1985, 50 (08) :1246-1255
[3]   UDP-GLUCURONOSYLTRANSFERASE ACTIVITIES - GUIDELINES FOR CONSISTENT INTERIM TERMINOLOGY AND ASSAY CONDITIONS [J].
BOCK, KW ;
BURCHELL, B ;
DUTTON, GJ ;
HANNINEN, O ;
MULDER, GJ ;
OWENS, IS ;
SIEST, G ;
TEPHLY, TR .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (06) :953-955
[4]   Glucuronidation in humans - Pharmacogenetic and developmental aspects [J].
de Wildt, SN ;
Kearns, GL ;
Leeder, JS ;
van den Anker, JN .
CLINICAL PHARMACOKINETICS, 1999, 36 (06) :439-452
[5]   Herb-drug interactions [J].
Fugh-Berman, A .
LANCET, 2000, 355 (9198) :134-138
[6]  
GELBOIN HV, 1993, PHARMACOL REV, V45, P413
[7]  
GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596
[8]  
Guengerich F P, 1997, Adv Pharmacol, V43, P7, DOI 10.1016/S1054-3589(08)60200-8
[9]  
GUENGERICH FP, 1994, TOXICOL LETT, V70, P133
[10]  
GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051